UT Research Foundation licensee Veru, Inc. announced on April 11, 2022, that their Phase 3 clinical trial of sabizabulin as an oral therapy for hospitalized severe COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and death showed the drug to be safe and effective. The trial was halted early due to the (read more)
HSC Office
UT pharmacy students developing device to individualize the smoking cessation process
Smoking is one of the most prominent causes of preventable disease each year in the United States. According to the 2020 National Survey on Drug Use and Health, 57.3 million people reported tobacco or nicotine vaping use in the past month. Meanwhile, a 2017 study of smokers from the Centers for Disease Control and Prevention (read more)
UTRF Inventor Spotlight: Dr. Nawajes Mandal
UTHSC researcher studies sphingolipid signaling in ocular and neurodegenerative disease and diabetes Dr. Nawajes Mandal has spent his career at the University of Tennessee Health Science Center (UTHSC) trying to better understand lipid and sphingolipid signaling in ocular and neurodegenerative disease and diabetes. One of his current projects may help slow the progression of retinal degeneration, (read more)